Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Interindividual variation in the pharmacokinetics of Delta9-tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9.

Clinical pharmacology and therapeutics - 1 Mar 2009

Sachse-Seeboth C, Pfeil J, Sehrt D, Meineke I, Tzvetkov M, Bruns E, Poser W, Vormfelde S V, Brockmöller J

Abstract excerpt

The impact of the CYP2C9 polymorphism on the pharmacokinetics of orally administered 9-tetrahydrocannabinol (THC) was studied in 43 healthy volunteers. THC pharmacokinetics did not differ by CYP2C9*2 allele status. However, the median area under the curve of THC was threefold higher and that of 1...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Alleles
Share to Aryl Hydrocarbon Hydroxylases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C9

Share to Gene Frequency

Share to Polymorphism, Genetic

Share to Sex Factors

Share to Young Adult

Source

Identifiers

PMID: 19005461
DOI: 10.1038/clpt.2008.213

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19005461-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

Interindividual variation in the pharmacokinetics of Delta9-tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9.PMID 19005461Read ↗

Cytochrome P450–catalyzed hydroxylation of Δ8-tetrahydrocannabinol and implications for pharmacogeneticsSemantic proximity Read ↗

Toxicogenetic analysis of Δ9-THC-metabolizing enzymes.Semantic proximity Read ↗

Assessing the influence of CYP2C9 and CYP2C19 genotypes on the metabolism of CBD-cannabis after controlled single and repetitive consumption.Semantic proximity Read ↗

Genotype-Specific Safety and Pharmacokinetics of Cannabidiol in Healthy Volunteers.Semantic proximity Read ↗

Effect of CYP2C9*3 mutant variants on meloxicam pharmacokinetics in a healthy Chinese population.Semantic proximity Read ↗

Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans.Semantic proximity Read ↗

Lornoxicam pharmacokinetics in relation to cytochrome P450 2C9 genotype.Semantic proximity Read ↗

The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects.Semantic proximity Read ↗

Lack of differences in diclofenac (a substrate for CYP2C9) pharmacokinetics in healthy volunteers with respect to the single CYP2C9*3 allele.Semantic proximity Read ↗

Severe phenytoin intoxication in a subject homozygous for CYP2C9*3.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.